CQDM Funds Six Collaborative R&D Projects Totaling Over $10M to Accelerate Development and De‑Risk Biopharmaceutical Innovation in Québec
FIND OUT MOREThis is some text inside of a div block.
ALL
Creators of next generation treatments
for inflammation and pain
CQDM funding supports SPMTherapeutics’ maresin-derived compounds developmentconducted within acollaborative project with CHU de Québec–Université Laval in systemic lupuserythematosus.
One of SPM Therapeutics’ programsfor the development of maresins-derived compounds is supported by CQDM fundingthrough a collaborative project with CHU de Québec–Université Laval on systemiclupus erythematosus
For more details on this announcement, please refer to the official press release.